The US healthcare system is evolving towards a more integrated approach to improving the health of Americans. Greater availability of health insurance through the Affordable Care Act and new organizational models such as integrated healthcare systems are leading health care providers and insurers to consider the totality of costs and benefits, instead of focusing on costs and benefits of individual service delivery ?silos.? For substance users, parity requirements for substance use disorder (SUD) and mental health insurance coverage and health insurance expansion present new opportunities for integrated care. They also present new opportunities and challenges for treating HCV-infected and HIV-infected substance users with highly effective and expensive medications. Both the broad societal economic impact and the health economic benefits for individuals of SUD, HCV, and HIV treatment need to be evaluated and communicated to clinical and policy decision makers in the context of this new environment. The overall specific aim of our P30 Center of Excellence proposal entitled ?Health Economics of Substance Use Disorder, HCV, and HIV Treatment in the Era of Integrated Health Care? is to develop and disseminate economic evidence that informs substance use treatment policy and HCV and HIV care of substance users, and to increase the impact of this research by addressing the needs of integrated healthcare system providers and payers. Our proposed Center (CHERISH: Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV) includes Methodology, HCV and HIV, Dissemination and Policy, Pilot Grant and Training, and Administrative Cores, a Policy Advisory Board, and a Center Advisory Board. The Core leaders and investigators have extensive experience with multi-institutional collaborations and several previous and ongoing collaborations. They will draw on a wider circle of experts involved with each of the NIH-supported research projects. CHERISH will be led by an established national expert in SUD, HCV, and HIV health economic research who has substantial management experience. We will innovatively use web-based technology to supplement frequent in-person meetings and support a structured management process and administrative tracking system. The proposed Center will serve as a national SUD health economics research resource, furthering scientific collaborations among researchers, providing feedback to these researchers from stakeholders, and conducting outreach to clinical and policy decision makers. Such interaction between researchers and decision makers is essential for NIH-funded research on SUD treatment strategies to have its greatest impact. Through pilot grants and associated training activities, we will provide new opportunities for training, mentoring and career development for researchers in the field of SUD, HCV, and HIV health economics. These activities will yield a new cohort of investigators with the skills needed to conduct methodologically sound and innovative SUD economic research to inform SUD, HCV, and HIV treatment policy.

Public Health Relevance

The overall specific aim of our proposed Center is to develop and disseminate economic evidence that informs substance use treatment policy and HCV and HIV care of substance users, and to increase the impact of this research by addressing the needs of integrated healthcare system providers and payers. The proposed Center will serve as a national SUD health economics research resource, furthering scientific collaborations among researchers, administering pilot grants and conducting training activities, providing feedback to economic researchers from stakeholders, and conducting outreach to clinical and policy decision makers. Such interaction between economic researchers and decision makers is essential for NIH-funded research on SUD treatment strategies to have its greatest impact.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
3P30DA040500-05S1
Application #
9793440
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Duffy, Sarah Q
Project Start
2015-07-15
Project End
2020-11-30
Budget Start
2019-05-01
Budget End
2020-11-30
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Other Health Professions
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Kapadia, Shashi N; Jeng, Philip J; Schackman, Bruce R et al. (2018) State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals. Clin Infect Dis 66:1618-1620
Freiman, J Morgan; Jacobson, Karen R; Muyindike, Winnie R et al. (2018) Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. J Acquir Immune Defic Syndr 77:405-412
Friedmann, Peter D; Wilson, Donna; Nunes, Edward V et al. (2018) Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder? J Subst Abuse Treat 85:61-65
Kapadia, Shashi N; Wu, Chunyuan; Mayer, Kenneth H et al. (2018) No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. PLoS One 13:e0206577
McCollister, Kathryn E; Yang, Xuan; Murphy, Sean M et al. (2018) Criminal justice measures for economic data harmonization in substance use disorder research. Health Justice 6:17
Chen, Donna T; Ko, Tomohiro M; Allen, Ashleigh A et al. (2018) Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision. J Empir Res Hum Res Ethics 13:160-172
Graves, Rachel L; Andreyeva, Elena; Perrone, Jeanmarie et al. (2018) Naloxone Availability and Pharmacy Staff Knowledge of Standing Order for Naloxone in Pennsylvania Pharmacies. J Addict Med :
Liang, Di; Bao, Yuhua; Wallace, Mark et al. (2018) Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993-2014. Addiction 113:2060-2070
Graves, Rachel L; Tufts, Christopher; Meisel, Zachary F et al. (2018) Opioid Discussion in the Twittersphere. Subst Use Misuse 53:2132-2139
Schackman, Bruce R; Gutkind, Sarah; Morgan, Jake R et al. (2018) Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. Drug Alcohol Depend 185:411-420

Showing the most recent 10 out of 93 publications